RVU — Ryvu Therapeutics SA Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Ryvu Therapeutics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.

	2020 December 31st	C2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-31.7	-79.1	-83.8	-92.1	-111
Depreciation
Deferred Taxes
Non-Cash Items	-5.8	22.5	31.4	10.9	-7.96
Discontinued Operations
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	13.6	-9.22	61.2	-14.3	-20.6
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-10.6	-58.9	21.3	-84.5	-129
Capital Expenditures	-34.2	-12	-9.29	-201	-5.9
Purchase of Fixed Assets
Other Investing Cash Flow Items	-21.8	20	9.98	5.65	143
Sale of Business
Sale of Fixed Assets
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-55.9	8.05	0.69	-196	137
Financing Cash Flow Items	-8.44	0.821	0.057	250	-0.006
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	131	-2.15	-2.46	241	94.2
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	64.1	-53	18.7	-44	102